acute myeloid leukemia
Conditions
Interventions
Experimental group:Induced remission: Venecola + azacabine
Consolidation therapy (option A or B according to patient's wishes) : Option A (Vinecola + cytarabine + clatribin
Venecola + cytarabine) followed
Plan B (Vinecra + Idabicin + cytarabine
Maintenance period: azacytidine.
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Elderly patients with AML diagnosed in accordance with WHO guidelines (2016 edition), aged >= 60 years; 2.Not suitable for standard induction chemotherapy regimens; 3.Eastern Cooperative Oncology Group performance-status score of 0 or 3; 4.The patients and their family members agreed and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1.Previous treatment for AML (including hypomethylating agents and other chemotherapy drugs); 2.Infiltration of the central nervous system; 3.Drugs use history affecting CYP3A within 7 days before enrollment; 4.Patients considered by the investigator to be unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Complete remission;Complete remission with incomplete blood count recovery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to response;Duration of response;Rates of death;Recurrence rate; | — |
Countries
China
Contacts
Public ContactZhao Long
The First Hospital of Lanzhou University
Outcome results
None listed